<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Blood</journal-id>
<journal-id journal-id-type="iso-abbrev">Blood</journal-id>
<journal-id journal-id-type="hwp">bloodjournal</journal-id>
<journal-id journal-id-type="pmc">blood</journal-id>
<journal-id journal-id-type="publisher-id">Blood</journal-id>
<journal-title-group>
<journal-title>Blood</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-4971</issn>
<issn pub-type="epub">1528-0020</issn>
<publisher>
<publisher-name>American Society of Hematology</publisher-name>
<publisher-loc>Washington, DC</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26679864</article-id>
<article-id pub-id-type="pmc">4797024</article-id>
<article-id pub-id-type="publisher-id">2015/667923</article-id>
<article-id pub-id-type="doi">10.1182/blood-2015-09-667923</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>36</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Red Cells, Iron, and Erythropoiesis</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dulmovits</surname>
<given-names>Brian M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Appiah-Kubi</surname>
<given-names>Abena O.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Papoin</surname>
<given-names>Julien</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hale</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Mingzhu</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Abed</surname>
<given-names>Yousef</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Didier</surname>
<given-names>Sebastien</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gould</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Husain-Krautter</surname>
<given-names>Sehba</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Sharon A.</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Kyle W. H.</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vlachos</surname>
<given-names>Adrianna</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Allen</surname>
<given-names>Steven L.</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taylor</surname>
<given-names>Naomi</given-names>
</name>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marambaud</surname>
<given-names>Philippe</given-names>
</name>
<xref ref-type="aff" rid="aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>An</surname>
<given-names>Xiuli</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gallagher</surname>
<given-names>Patrick G.</given-names>
</name>
<xref ref-type="aff" rid="aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mohandas</surname>
<given-names>Narla</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lipton</surname>
<given-names>Jeffrey M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Johnson M.</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff10">10</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Blanc</surname>
<given-names>Lionel</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0185-6260</contrib-id>
</contrib>
<aff id="aff1"><label>1</label>Laboratory of Developmental Erythropoiesis, The Feinstein Institute for Medical Research, Manhasset, NY; </aff>
<aff id="aff2"><label>2</label>Hofstra North Shore-LIJ School of Medicine, Hempstead, NY; </aff>
<aff id="aff3"><label>3</label>Red Cell Physiology Laboratory, New York Blood Center, New York, NY; </aff>
<aff id="aff4"><label>4</label>Center for Molecular Innovation, The Feinstein Institute for Medical Research, Manhasset, NY; </aff>
<aff id="aff5"><label>5</label>BioTheryX Inc, San Diego, CA; </aff>
<aff id="aff6"><label>6</label>North Shore-LIJ Cancer Institute, Lake Success, NY; </aff>
<aff id="aff7"><label>7</label>Institut de Génétique Moléculaire de Montpellier, Unité Mixte de Recherche 5535, Montpellier, France; </aff>
<aff id="aff8"><label>8</label>Litwin Zucker Research Center, The Feinstein Institute for Medical Research, Manhasset, NY; </aff>
<aff id="aff9"><label>9</label>Yale Center for Excellence in Molecular Hematology, Yale University School of Medicine, New Haven CT; and </aff>
<aff id="aff10"><label>10</label>Les Nelkin Memorial Pediatric Oncology Laboratory, The Feinstein Institute for Medical Research, Manhasset, NY</aff>
</contrib-group>
<author-notes>
<fn fn-type="equal" id="fn1">
<label>*</label>
<p>B.M.D. and A.O.A.-K. contributed equally to this study.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>17</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>17</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>3</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>127</volume>
<issue>11</issue>
<fpage>1481</fpage>
<lpage>1492</lpage>
<history>
<date date-type="received">
<day>01</day>
<month>9</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 by The American Society of Hematology</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="1481.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<related-article ext-link-type="doi" id="d36e319" related-article-type="article-reference" xlink:href="10.1182/blood-2016-01-689018">Lowrey</related-article>
<abstract abstract-type="teaser">
<p><bold>Publisher's Note:</bold> There is an <related-article ext-link-type="doi" id="d36e326" related-article-type="article-reference" xlink:href="10.1182/blood-2016-01-689018">Inside <italic>Blood</italic> Commentary</related-article> on this article in this issue.</p>
</abstract>
<abstract abstract-type="executive-summary">
<title>Key Points</title>
<p>
<list list-type="bullet">
<list-item>
<p>Pomalidomide selectively targets BCL11A and SOX6 to induce γ-globin synthesis.</p>
</list-item>
<list-item>
<p>The mechanism of action of pomalidomide during erythropoiesis is independent of IKZF1 degradation, in contrast to multiple myeloma.</p>
</list-item>
</list>
</p>
</abstract>
<abstract>
<p>Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin. Pomalidomide, a third-generation immunomodulatory drug, was proposed to induce fetal hemoglobin production by an unknown mechanism. Here, we report that pomalidomide induced a fetal-like erythroid differentiation program, leading to a reversion of γ-globin silencing in adult human erythroblasts. Pomalidomide acted early by transiently delaying erythropoiesis at the burst-forming unit-erythroid/colony-forming unit-erythroid transition, but without affecting terminal differentiation. Further, the transcription networks involved in γ-globin repression were selectively and differentially affected by pomalidomide including BCL11A, SOX6, IKZF1, KLF1, and LSD1. IKAROS (IKZF1), a known target of pomalidomide, was degraded by the proteasome, but was not the key effector of this program, because genetic ablation of <italic>IKZF1</italic> did not phenocopy pomalidomide treatment. Notably, the pomalidomide-induced reprogramming was conserved in hematopoietic progenitors from individuals with sickle cell anemia. Moreover, multiple myeloma patients treated with pomalidomide demonstrated increased in vivo γ-globin levels in their erythrocytes. Together, these data reveal the molecular mechanisms by which pomalidomide reactivates fetal hemoglobin, reinforcing its potential as a treatment for patients with β-hemoglobinopathies.</p>
</abstract>
<funding-group>
<award-group>
<funding-source id="CS100">National Institutes of Health</funding-source>
</award-group>
</funding-group>
<counts>
<page-count count="12"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>